These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 19047121)

  • 1. Phase I/II study of G3139 (Bcl-2 antisense oligonucleotide) in combination with doxorubicin and docetaxel in breast cancer.
    Moulder SL; Symmans WF; Booser DJ; Madden TL; Lipsanen C; Yuan L; Brewster AM; Cristofanilli M; Hunt KK; Buchholz TA; Zwiebel J; Valero V; Hortobagyi GN; Esteva FJ
    Clin Cancer Res; 2008 Dec; 14(23):7909-16. PubMed ID: 19047121
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase I trial of a Bcl-2 antisense (G3139) and weekly docetaxel in patients with advanced breast cancer and other solid tumors.
    Marshall J; Chen H; Yang D; Figueira M; Bouker KB; Ling Y; Lippman M; Frankel SR; Hayes DF
    Ann Oncol; 2004 Aug; 15(8):1274-83. PubMed ID: 15277270
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase I pharmacokinetic and pharmacodynamic correlative study of the antisense Bcl-2 oligonucleotide g3139, in combination with carboplatin and paclitaxel, in patients with advanced solid tumors.
    Liu G; Kolesar J; McNeel DG; Leith C; Schell K; Eickhoff J; Lee F; Traynor A; Marnocha R; Alberti D; Zwiebel J; Wilding G
    Clin Cancer Res; 2008 May; 14(9):2732-9. PubMed ID: 18451239
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I Trial of G3139, a bcl-2 antisense oligonucleotide, combined with doxorubicin and cyclophosphamide in children with relapsed solid tumors: a Children's Oncology Group Study.
    Rheingold SR; Hogarty MD; Blaney SM; Zwiebel JA; Sauk-Schubert C; Chandula R; Krailo MD; Adamson PC;
    J Clin Oncol; 2007 Apr; 25(12):1512-8. PubMed ID: 17442993
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and biologic activity of intravenous BCL-2 antisense oligonucleotide (G3139) and taxane chemotherapy in patients with advanced cancer.
    Morris MJ; Cordon-Cardo C; Kelly WK; Slovin SF; Siedlecki K; Regan KP; DiPaola RS; Rafi M; Rosen N; Scher HI
    Appl Immunohistochem Mol Morphol; 2005 Mar; 13(1):6-13. PubMed ID: 15722787
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Phase I pharmacokinetic and biological correlative study of oblimersen sodium (genasense, g3139), an antisense oligonucleotide to the bcl-2 mRNA, and of docetaxel in patients with hormone-refractory prostate cancer.
    Tolcher AW; Kuhn J; Schwartz G; Patnaik A; Hammond LA; Thompson I; Fingert H; Bushnell D; Malik S; Kreisberg J; Izbicka E; Smetzer L; Rowinsky EK
    Clin Cancer Res; 2004 Aug; 10(15):5048-57. PubMed ID: 15297406
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oblimersen combined with docetaxel, adriamycin and cyclophosphamide as neo-adjuvant systemic treatment in primary breast cancer: final results of a multicentric phase I study.
    Rom J; von Minckwitz G; Eiermann W; Sievert M; Schlehe B; Marmé F; Schuetz F; Scharf A; Eichbaum M; Sinn HP; Kaufmann M; Sohn C; Schneeweiss A
    Ann Oncol; 2008 Oct; 19(10):1698-705. PubMed ID: 18477581
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I trial of BCL-2 antisense oligonucleotide (G3139) administered by continuous intravenous infusion in patients with advanced cancer.
    Morris MJ; Tong WP; Cordon-Cardo C; Drobnjak M; Kelly WK; Slovin SF; Terry KL; Siedlecki K; Swanson P; Rafi M; DiPaola RS; Rosen N; Scher HI
    Clin Cancer Res; 2002 Mar; 8(3):679-83. PubMed ID: 11895895
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I study of G3139, a bcl-2 antisense oligonucleotide, combined with carboplatin and etoposide in patients with small-cell lung cancer.
    Rudin CM; Kozloff M; Hoffman PC; Edelman MJ; Karnauskas R; Tomek R; Szeto L; Vokes EE
    J Clin Oncol; 2004 Mar; 22(6):1110-7. PubMed ID: 15020613
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I study of oblimersen sodium, an antisense to Bcl-2, in untreated older patients with acute myeloid leukemia: pharmacokinetics, pharmacodynamics, and clinical activity.
    Marcucci G; Stock W; Dai G; Klisovic RB; Liu S; Klisovic MI; Blum W; Kefauver C; Sher DA; Green M; Moran M; Maharry K; Novick S; Bloomfield CD; Zwiebel JA; Larson RA; Grever MR; Chan KK; Byrd JC
    J Clin Oncol; 2005 May; 23(15):3404-11. PubMed ID: 15824414
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of Bcl-2 antisense oligonucleotide (G3139) combined with doxorubicin in SCID mice bearing human breast cancer solid tumor xenografts.
    Lopes de Menezes DE; Mayer LD
    Cancer Chemother Pharmacol; 2002 Jan; 49(1):57-68. PubMed ID: 11855753
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular and pharmacokinetic properties associated with the therapeutics of bcl-2 antisense oligonucleotide G3139 combined with free and liposomal doxorubicin.
    Lopes de Menezes DE; Hudon N; McIntosh N; Mayer LD
    Clin Cancer Res; 2000 Jul; 6(7):2891-902. PubMed ID: 10914739
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II study of G3139, a Bcl-2 antisense oligonucleotide, in combination with dexamethasone and thalidomide in relapsed multiple myeloma patients.
    Badros AZ; Goloubeva O; Rapoport AP; Ratterree B; Gahres N; Meisenberg B; Takebe N; Heyman M; Zwiebel J; Streicher H; Gocke CD; Tomic D; Flaws JA; Zhang B; Fenton RG
    J Clin Oncol; 2005 Jun; 23(18):4089-99. PubMed ID: 15867202
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase II, pharmacokinetic, and biological correlative study of oblimersen sodium and docetaxel in patients with hormone-refractory prostate cancer.
    Tolcher AW; Chi K; Kuhn J; Gleave M; Patnaik A; Takimoto C; Schwartz G; Thompson I; Berg K; D'Aloisio S; Murray N; Frankel SR; Izbicka E; Rowinsky E
    Clin Cancer Res; 2005 May; 11(10):3854-61. PubMed ID: 15897586
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I study of apoptosis gene modulation with oblimersen within preoperative chemotherapy in patients with primary breast cancer.
    Rom J; von Minckwitz G; Marmé F; Ataseven B; Kozian D; Sievert M; Schlehe B; Schuetz F; Scharf A; Kaufmann M; Sohn C; Schneeweiss A
    Ann Oncol; 2009 Nov; 20(11):1829-35. PubMed ID: 19605509
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A pilot trial of G3139, a bcl-2 antisense oligonucleotide, and paclitaxel in patients with chemorefractory small-cell lung cancer.
    Rudin CM; Otterson GA; Mauer AM; Villalona-Calero MA; Tomek R; Prange B; George CM; Szeto L; Vokes EE
    Ann Oncol; 2002 Apr; 13(4):539-45. PubMed ID: 12056703
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase 1 and pharmacodynamic studies of G3139, a Bcl-2 antisense oligonucleotide, in combination with chemotherapy in refractory or relapsed acute leukemia.
    Marcucci G; Byrd JC; Dai G; Klisovic MI; Kourlas PJ; Young DC; Cataland SR; Fisher DB; Lucas D; Chan KK; Porcu P; Lin ZP; Farag SF; Frankel SR; Zwiebel JA; Kraut EH; Balcerzak SP; Bloomfield CD; Grever MR; Caligiuri MA
    Blood; 2003 Jan; 101(2):425-32. PubMed ID: 12393493
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase II study of docetaxel, doxorubicin, and infusional 5-fluorouracil in the treatment of patients with locally advanced breast cancer.
    Thatai LC; Vishnubhotla P; Biernat L; Flaherty L; LoRusso P; Simon M; Stephens D; Vereeke K; Abrams J; Bouwman D; Philip PA
    Am J Clin Oncol; 2006 Oct; 29(5):484-9. PubMed ID: 17023784
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-survival in responding patients with metastatic breast cancer treated with doxorubicin-docetaxel combination. A multicentre phase II trial.
    Mattioli R; Lippe P; Massacesi C; Cappelletti C; Nacciarriti D; Bisonni R; Graziano F; Menichetti ET; Imperatori L; Testa E; Laici G; Balletra A; Silva RR
    Anticancer Res; 2004; 24(5B):3257-61. PubMed ID: 15510620
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multicenter randomized trial comparing sequential with concomitant administration of doxorubicin and docetaxel as first-line treatment of metastatic breast cancer: a Spanish Breast Cancer Research Group (GEICAM-9903) phase III study.
    Alba E; Martín M; Ramos M; Adrover E; Balil A; Jara C; Barnadas A; Fernández-Aramburo A; Sánchez-Rovira P; Amenedo M; Casado A;
    J Clin Oncol; 2004 Jul; 22(13):2587-93. PubMed ID: 15226326
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.